R-Biopharm AG: Flu tests from R-Biopharm also detect new virus variants
Darmstadt, November 25, 2022: The flu season has begun and different virus variants are also circulating in Germany. With the flu tests from biotechnology company R-Biopharm, patients quickly have certainty: Its RIDA®GENE Flu assays also reliably detect the two novel variants. The company made the announcement with regard to influenza A H1N1pdm09, which is circulating primarily in the United Kingdom, and the H3N2 subtype, which was rampant in Denmark in the spring and is currently dominating influenza activity in Germany.
"Mutations in the target gene (MP gene) can affect the diagnostic performance of influenza screening assays, producing false-negative test results," explains Dr. Andreas Simons, Head of Product Management at R-Biopharm. " Alignments of the detection systems we used with the described sequences of the two novel virus variants showed no mismatches. Their reliable detection is not affected by the described mutations."
This means laboratories can continue to reliably confirm or rule out influenza infections using R-Biopharm's RIDA®GENE (PG0505, PG0545, PG6825) assays. The tests are multiplex real-time RT-PCR for the direct qualitative detection of influenza viruses.
R-Biopharm AG, located in Darmstadt, is one of Germany's leading biotechnology companies. Founded in 1988, the company is family-run in the second generation and considers itself as a pioneer for health and quality of life. Its aspiration: to provide the highest possible precision, safety, clarity and certainty in prevention, therapy and healing. To this end, R-Biopharm develops technologies, products and solutions for Clinical Diagnostics, Nutrition Care and Food and Feed Analytics – and does so in internationally recognized top quality. R-Biopharm is the world market leader for test systems in the field of allergen analysis.
R-Biopharm unites research, development and sales under one roof in order to respond to ever new challenges with agile processes and to accompany the steadily growing world population into a new health era. The company is represented in more than 120 countries – through 29 subsidiaries and 120 distributors. It employs around 1,400 people worldwide (690 at its headquarters in Darmstadt) and was repeatedly recognized with the "Sustainability Award" for sustainable and profitable growth.
Head of Corporate Brand Communication
An der neuen Bergstraße 17
Phone: 0 61 51 - 81 02-538
Mobile: 0 160 - 55 273 60
Fax: 0 61 51 - 81 02-40
About news aktuell GmbH
news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Game-changing Public Transport: HOLON and Valtech Mobility join Forces22.2.2024 14:00:00 CET | Press release
Long-term strategic partnership Collaboration on fully autonomous, comfortable, inclusive and sustainable public transport Joint development of cloud platform for HOLON Mover
Hearing loss company Acousia announces first patient enrolled in its Phase 2 PROHEAR-Study15.2.2024 09:00:00 CET | Press release
Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, just announced the randomization of the first patient for the PROHEAR-Study. The PROHEAR-Study is a placebo-controlled, Phase 2a study with split-body design, which investigates the otoprotective efficacy of ACOU085 in patients with testicular cancer undergoing high-dose cisplatin-based chemotherapy regimens (cis-Pt ≥300 mg/m2).
Two years of war in Ukraine: EU citizens back joint defence policy15.2.2024 08:00:00 CET | Press release
The situation for Ukraine is deteriorating in the 2024 election year in the EU and US. While a majority continues to support aid to Ukraine in both the EU and in Germany, this applies primarily to supporters of centrist parties. However, a joint European defence policy enjoys majority backing across party lines: 87 per cent of all EU citizens, and 86 per cent of Germans, support the idea.
PAPACKS: 100-Million Coffee Capsule Deal: PAPACKS and EURO-CAPS Conquer the Market with Plastic-Free Innovation and Win the Prestigious WorldStar Packaging Award13.2.2024 09:45:00 CET | Press release
The coffee capsule, developed together in a more than five-year fantastic collaboration between Euro-Caps and PAPACKS, is made from renewable, FSC®-certified raw materials, representing a significant advancement in the sustainable packaging industry. It greatly minimizes waste and optimizes resource usage.
The 2025 HÄUSER-AWARD: simply good houses. The search is on for individual detached houses that are suitable for everyday life12.2.2024 10:15:27 CET | Press release
Building has become increasingly complex and complicated in recent years, especially in terms of construction and building technology. But even in architecture, the most convincing solutions do not necessarily have to be the most elaborate - on the contrary. Focusing on the essentials, rethinking and redefining requirements is more important than ever in times of climate change, energy crisis and scarce resources - and makes both economic and ecological sense.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom